The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 22, 2013
Filed:
Mar. 16, 2009
Shigeharu Fukuda, Okayama, JP;
Chie Ushio, Okayama, JP;
Harumi Ariyasu, Okayama, JP;
Tohru Kayano, Okayama, JP;
Toshio Ariyasu, Okayama, JP;
Tsunetaka Ohta, Okayama, JP;
Shigeharu Fukuda, Okayama, JP;
Chie Ushio, Okayama, JP;
Harumi Ariyasu, Okayama, JP;
Tohru Kayano, Okayama, JP;
Toshio Ariyasu, Okayama, JP;
Tsunetaka Ohta, Okayama, JP;
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama, JP;
Abstract
The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient.